Therefore, mutations and deletions of proteins associated with this pathway on tumor cells, such as JAK1 and JAK2, STAT1, IRF1, and other IFN receptor chains, can lead to drug resistance to immunocheckpoint inhibitors [17]. The gene discussed is IRF1; the disease is neoplasm.